Subcutaneous · GLP-1 / glucagon dual
DA-1726
1 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
1
Ongoing
1
Recruiting
1
Completed
0
Sites
1
Countries
1
Endpoints
4
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
1
Trials by status
Recruiting
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
3
Other (unclassified)
1
Top 20 metrics across this asset's endpoints
Treatment-emergent AEs (any)Safety/PK
1
Plasma concentration (steady state)Safety/PK
1
Immunogenicity (ADA)Safety/PK
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT06252220First in Human Study in Subjects With Obesity, But Otherwise Healthy | DA-1726 Obesity / overweight | - | Ph 1 | Recruiting | 1 | Nov 2026 | - |
Showing 1-1 of 1 trials